No Data
HK Stocks Update: Pharmaceutical stocks continue to strengthen, AstraZeneca-B (01541) expands its gains in the afternoon. Hong Kong approval mechanism will be extended to all new drugs starting from November.
Pharmaceutical stocks continue to strengthen, as of the time of publication, Wuxi Bio-B (01541) rose 22.76%, to 7.65 Hong Kong dollars; Zai Lab (09688) rose 15.25%, to 25.7 Hong Kong dollars; Hoyo-B (02256) rose 8.82%, to 4.32 Hong Kong dollars; Tigermed (03347) rose 11.65%, to 41.2 Hong Kong dollars; Wuxi Bio (02269) rose 6.68%, to 17.56 Hong Kong dollars.
Wah Yuet - B [02256] is now trading at HK$4.37, up 10.08%.
As of 10:34, China Overseas Land & Investment Limited [02256] reported a price of 4.37 Hong Kong dollars, an increase of 0.4 Hong Kong dollars or 10.08% compared to the previous closing price of 3.97 Hong Kong dollars. The turnover was 21.8823 million Hong Kong dollars. The highest price today was 4.37 Hong Kong dollars and the lowest price was 3.95 Hong Kong dollars. Based on the closing price of yesterday, the 10-day average price is 3.65 Hong Kong dollars, the 50-day average price is 3.30 Hong Kong dollars, and the current P/E ratio is -5.40 times. The 14-day relative strength index is 55.94.
Abbisko Cayman's Unit Presents Two Preclinical Cancer Programs at the Barcelona Conference
Viva-B (02256.HK) released two preclinical research results at the ENA conference in Spain.
Wu Yu-B (02256.HK) announced that the two preclinical research results of its subsidiary shanghai Wu Yu biomedical technology were released at the 36th International Molecular Targeted Cancer Treatment Conference (ENA Conference) held in Barcelona, Spain in October. It was introduced that the above two research results respectively demonstrate the potential best-in-class PRMT5*MTA inhibitor ABSK131 in Wu Yu medicine's research pipeline, as well as the latest preclinical research progress of the oral KRASG12D small molecule inhibitor ABSK141. (js/w)~
Hoya-B (02256.HK) subsidiary released preliminary research results for PRMT5*MTA and oral KRASG12D projects at the EORTC-NCI-AACR conference.
GeLunHui October 23rd | Heyu-B (02256.HK) announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medical) announced that the results of two preclinical studies of Heyu Medical were presented at the 36th International Molecular Target and Cancer Therapy Conference (EORTC-NCI-AACR Conference, "ENA Conference") held in Barcelona, Spain in October. The two research achievements respectively demonstrated Heyu Medical's potential best-in-class PRMT5*MTA inhibitor ABSK131 and oral KRASG12D small molecule inhibitor in its research pipeline.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
No Data
No Data